With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP's status as a leading RNAi delivery technology; the effectiveness of Tekmira's TKM-Ebola product candidate as a treatment for the Ebola virus; the developmental milestones and approvals required to trigger funding for TKM-Ebola from the TMT program; and the timing and quantum of payments to be received under contracts with Tekmira's collaborative partners including the U.S. Government. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the U.S. Government may reduce or cancel certain defense spending, including Tekmira's contract to develop TKM-Ebola; TKM-Ebola may never receive FDA approval; there may be no further innovations to Tekmira's LNP technology platform; further development of Tekmira's LNP technology may not support late stage clinical development and commercialization of TKM-Ebola or other LNP-enabled products; the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; and Tekmira's development programs, including TKM-Ebola, will not result in expected results on a timely basis, or at all.
CONTACT: Investors Jodi Regts Director, Investor Relations Phone: 604-419-3234 Email: firstname.lastname@example.org Media David Ryan Longview Communications Inc. Phone: 416-649-8007 Email: email@example.com